Browse PPIP5K2

Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol
Domain PF00328 Histidine phosphatase superfamily (branch 2)
Function

Bifunctional inositol kinase that acts in concert with the IP6K kinases IP6K1, IP6K2 and IP6K3 to synthesize the diphosphate group-containing inositol pyrophosphates diphosphoinositol pentakisphosphate, PP-InsP5, and bis-diphosphoinositol tetrakisphosphate, (PP)2-InsP4. PP-InsP5 and (PP)2-InsP4, also respectively called InsP7 and InsP8, regulate a variety of cellular processes, including apoptosis, vesicle trafficking, cytoskeletal dynamics, exocytosis, insulin signaling and neutrophil activation. Phosphorylates inositol hexakisphosphate (InsP6) at positions 1 or 3 to produce PP-InsP5 which is in turn phosphorylated by IP6Ks to produce (PP)2-InsP4. Alternatively, phosphorylates at position 1 or 3 PP-InsP5, produced by IP6Ks from InsP6, to produce (PP)2-InsP4.

> Gene Ontology
 
Biological Process GO:0006020 inositol metabolic process
GO:0006066 alcohol metabolic process
GO:0016311 dephosphorylation
GO:0019751 polyol metabolic process
GO:0032958 inositol phosphate biosynthetic process
GO:0043647 inositol phosphate metabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044283 small molecule biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
Molecular Function GO:0000827 inositol-1,3,4,5,6-pentakisphosphate kinase activity
GO:0000828 inositol hexakisphosphate kinase activity
GO:0000829 inositol heptakisphosphate kinase activity
GO:0000832 inositol hexakisphosphate 5-kinase activity
GO:0003993 acid phosphatase activity
GO:0016776 phosphotransferase activity, phosphate group as acceptor
GO:0016791 phosphatase activity
GO:0033857 diphosphoinositol-pentakisphosphate kinase activity
GO:0042578 phosphoric ester hydrolase activity
GO:0052723 inositol hexakisphosphate 1-kinase activity
GO:0052724 inositol hexakisphosphate 3-kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04070 Phosphatidylinositol signaling system
Reactome R-HSA-1483249: Inositol phosphate metabolism
R-HSA-1430728: Metabolism
R-HSA-1855167: Synthesis of pyrophosphates in the cytosol
Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPIP5K2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPIP5K2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.72 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPIP5K2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1070.733
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3010.834
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0350.973
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2060.542
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1630.936
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2660.911
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1130.771
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.220.901
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0280.989
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3330.798
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0060.603
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0570.303
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPIP5K2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.84.110.70.0828
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.85.19.70.199
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPIP5K2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPIP5K2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPIP5K2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPIP5K2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPIP5K2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPIP5K2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPIP5K2
Namediphosphoinositol pentakisphosphate kinase 2
Aliases KIAA0433; VIP2; CFAP160; HISPPD1; histidine acid phosphatase domain containing 1; IP7K2; VIP1 homolog 2; his ......
Chromosomal Location5q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPIP5K2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.